GlassScriptPhysician profile
Monte F Jones
NPI 1700829249
$5,215.90
in general payments reported to CMS, 2019-2025
44 companies · $2,303 in 2025
The $2,303 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.29 · 2020: $44.57 · 2021: $43.11 · 2022: $314 · 2023: $963 · 2024: $1,498 · 2025: $2,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,664 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,664.22 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $784.45 | 2022-2025 | Imfinzi, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $458.20 | 2022-2025 | |
| Sobi, INC | $303.58 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $292.54 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $278.92 | 2023-2025 | Rybrevant, Tecvayli, Darzalex |
| Celgene Corporation | $274.79 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Pharmaessentia USA Corporation | $268.11 | 2023-2025 | Besremi |
| Lilly USA, LLC | $236.43 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $219.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $208.06 | 2020-2025 | Opdivo |
| Eisai INC. | $207.70 | 2022-2025 | |
| Gilead Sciences, INC. | $187.83 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $146.73 | 2023-2025 | Libtayo, Lynozyfic |
| Takeda Pharmaceuticals U.S.A., INC. | $142.72 | 2023-2025 | Advate, Vonvendi, Vpriv |
| Abbvie INC. | $138.55 | 2022-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $137.45 | 2019-2025 | |
| Amgen INC. | $137.02 | 2022-2023 | Lumakras, Kyprolis |
| Glaxosmithkline, LLC. | $105.53 | 2023-2025 | Ojjaara |
| Emd Serono, INC. | $95.56 | 2023-2025 | Bavencio |
| Daiichi Sankyo INC. | $77.71 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Astellas Pharma US INC | $51.07 | 2020-2024 | Padcev, Xtandi |
| Geron Corporation | $46.87 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $46.06 | 2025 | |
| Array Biopharma INC | $38.03 | 2024-2025 | Xalkori, Braftovi, Lorbrena |
| Acrotech Biopharma INC. | $37.87 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $36.40 | 2024-2025 | Ultomiris |
| Beigene USA, INC. | $27.85 | 2024 | Tevimbra |
| Incyte Corporation | $25.22 | 2025 | Monjuvi |
| Myriad Genetic Laboratories, INC. | $20.97 | 2025 | Precisetumor |
| Ge Healthcare | $20.96 | 2022 | |
| Caris Mpi, INC. | $19.79 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $19.30 | 2020 | |
| Pharmacosmos Therapeutics INC. | $19.11 | 2024 | Monoferric |
| Jazz Pharmaceuticals INC. | $18.70 | 2024 | |
| Recordati_rare_diseases_inc. | $18.63 | 2024 | Sylvant |
| Seagen INC. | $17.59 | 2019 | |
| Blueprint Medicines Corporation | $17.34 | 2022 | |
| Agios Pharmaceuticals, INC. | $17.02 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $15.32 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.